Ibrutinib and Hyperbilirubinaemia aggravated - a phase IV clinical study of FDA data

Summary:

Hyperbilirubinaemia aggravated is reported as a side effect among people who take Ibrutinib (ibrutinib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Posaconazole, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Hyperbilirubinaemia aggravated when taking Ibrutinib. It is created by eHealthMe based on reports of 13,522 people who have side effects when taking Ibrutinib from the FDA, and is updated regularly.

What is Ibrutinib?

Ibrutinib has active ingredients of ibrutinib. eHealthMe is studying from 13,529 Ibrutinib users. Check the latest studies of Ibrutinib.

What is Hyperbilirubinaemia aggravated?

Hyperbilirubinaemia aggravated (excess of bilirubin in the blood) is found to be associated with 811 drugs and 377 conditions by eHealthMe. Check the latest studies of Hyperbilirubinaemia aggravated.

On Jul, 16, 2026

13,522 people reported to have side effects when taking Ibrutinib.
Among them, 27 people (0.2%) have Hyperbilirubinaemia aggravated.

Could Ibrutinib cause Hyperbilirubinaemia aggravated?

Among these 27 people:

How long have people been on Ibrutinib when they have Hyperbilirubinaemia aggravated? *

What is the gender of people who have Hyperbilirubinaemia aggravated when taking Ibrutinib? *

female: 9.09 %
male: 90.91 %

What is the age of people who have Hyperbilirubinaemia aggravated when taking Ibrutinib? *

What are other drugs people take besides Ibrutinib? *

What are other side effects people have besides Hyperbilirubinaemia aggravated? *

Fever: 8 people, 29.63%
Thrombocytopenia (decrease of platelets in blood): 7 people, 25.93%
Alanine Aminotransferase Increased: 7 people, 25.93%
Aspartate Aminotransferase Increased: 6 people, 22.22%
Hypotension (abnormally low blood pressure): 6 people, 22.22%
Septic Shock (shock due to blood infection): 5 people, 18.52%
Infection: 5 people, 18.52%
Klebsiella Infection: 5 people, 18.52%
Enterococcal Infection: 5 people, 18.52%
Viral Haemorrhagic Cystitis (lower urinary tract symptoms that include haematuria and irritative voiding symptoms): 5 people, 18.52%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 14 people, 51.85%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 6 people, 22.22%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 5 people, 18.52%
Cystitis Noninfective (non-infectious inflammation of the wall of the bladder): 5 people, 18.52%
Immunodeficiency Disorders: 3 people, 11.11%
High Blood Pressure: 3 people, 11.11%
Mantle Cell Lymphoma Refractory (relapsed cancer of lymphocytes, a type of white blood cell): 2 people, 7.41%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 2 people, 7.41%
Lymphoma (cancer that begins in immune system cells): 2 people, 7.41%
Tumor Lysis Syndrome: 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrutinib and have Hyperbilirubinaemia aggravated?

- Check whether Hyperbilirubinaemia aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrutinib:

Ibrutinib (13,529 reports)

Browse all side effects of Ibrutinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperbilirubinaemia aggravated:

Hyperbilirubinaemia aggravated (811 drugs)

Browse all the conditions that are associated with Hyperbilirubinaemia aggravated:

Hyperbilirubinaemia aggravated (377 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Ibrutinib) and Ibrutinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.